Healthcare
Biotechnology
Technology
Acorda Therapeutics
$13.299876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$13.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.16 (1.22%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ACOR and other stocks, options, ETFs, and crypto commission-free!
About
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. Read More The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
CEO
Employees
474
Headquarters
Ardsley, New York
Founded
1995
Market Cap
622.63M
Price-Earnings Ratio
18.81
Dividend Yield
0.00
Average Volume
726.62K
High Today
$13.43
Low Today
$13.10
Open Price
$13.23
Volume
217.14K
52 Week High
$36.35
52 Week Low
$12.55
Collections
Healthcare
Biotechnology
Technology
Health
Therapy
US
North America
News
Yahoo Finance13h
See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
Acorda Therapeutics Inc NASDAQ/NGS:ACOR View full report here! Summary Bearish sentiment is moderate Bearish sentiment Short interest | Negative Short interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flow ETF/Index ownership | Neutral ETF activit...
MarketWatchMar 25
Acorda Therapeutics Inc.
Acorda (ACOR) delivered earnings and revenue surprises of 175.00% and 70.38%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
TradingNewsNowMar 21
Recent Fundamentals: Acorda Therapeutics (NASDAQ: ACOR)
Acorda Therapeutics trades as part of the biotechnology industry and healthcare sector. The company CEO is Ron Cohen. Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development and commercialization of novel therapies for the treatment of neurological disorders. Previous Intraday Trading Performance: The ACOR stock showed a previous change of -4.60% with an open at 14.36 and a close of 13.69. It reached an intraday high of 14.41 and a low of 13.51. Business W...
Price Paid on Robinhood
19% Lower
Right Now
52 Week Low
$12.55
Average Price Paid
$16.50
52 Week High
$36.35
Earnings
-$0.63
$0.05
$0.72
$1.40
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
â
Actual
Expected May 1